Ajax's lead program, AJ1-11095, is a first-in-class Type II JAK2 inhibitor currently in Phase 1 clinical development, with first proof-of-concept clinical data to be presented later in 2026
In his new role, Gregory will drive partnerships for the company’s large-scale molecule biologics business across Europe
The approval was driven by data from the Phase III TULIP-SC trial
Our company is prioritising deeper collaborations with CDMOs and biosimilar companies as part of its strategy to expand its footprint across India, Middle East, and Africa region
The collaboration will roll out an “agentic” AI platform across Merck’s research & development, manufacturing, commercial, and corporate operations
Once complete, the site will serve as AbbVie’s U.S. center of excellence for SVP manufacturing
Bulling brings extensive experience across the biopharma and CDMO landscape, with leadership roles spanning both drug substance and drug product operations
The deal the group says marks a decisive push deeper into severe infectious diseases and the build-out of a global specialty pharmaceuticals platform
It is actually a new ISO Class 5 controlled cleanroom designed to deliver washed, dried, and gamma-sterilized single-use assemblies ready for immediate use.
The cleanroom operates under stringent ISO Class 5 conditions, using ultrapure water and air systems
Subscribe To Our Newsletter & Stay Updated
